OPNT News and Press, Opiant Pharmaceuticals Inc. From 08/08/19

Opiant Pharmaceuticals (NASDAQ: OPNT ): Q2 EPS of $0.31 may not be comparable to consensus of -$0.55. More news on: Opiant Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SANTA MONICA, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it will report its financial results for the second quarter and six ...

Opiant Pharmaceuticals ( OPNT -0.3% ) inks an agreement with Sanofi ( SNY +0.5% ) under which the latter will manufacture OPNT004 (drinabant), in development for the treatment of acute cannabinoid overdose. More news on: Opiant Pharmaceuticals, Inc., Sanofi, Healthcare stocks news, ...

SANTA MONICA, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it has signed an agreement with Sanofi (NYSE:SNY) to manufacture Opiant’s...

The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly mee t tomorrow and Wednesday, June 11 & 12, to seek public input on the clinical utility and safety concerns associated with higher range opioid an...

Opiant Pharmaceuticals, Inc. (OPNT) Q1 2019 Earnings Conference Call May 9, 2019 16:30 ET Company Participants Brian Ritchie - IR, LifeSci Advisors Roger Crystal - CEO David O'Toole - CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald David Bautz - Zacks ...

Opiant Pharmaceuticals (NASDAQ: OPNT ): Q1 GAAP EPS of -$0.44 beats by $0.35 . More news on: Opiant Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SANTA MONICA, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today reported financial results for the three months ended March 31, 2019, ...

SANTA MONICA, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it will report its financial results for the first quarter ended Ma...

Laurence Doud III, former CEO of Rochester Drug Co-Operative, was indicted yesterday by a Manhattan federal grand jury on charges of narcotics conspiracy and conspiracy to defraud the Drug Enforcement Administration (DEA) related to the distribution of "tens of millions" of opioid painkill...